Stuart C Ray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2898678/publications.pdf

Version: 2024-02-01

		30047	19726
136	14,429	54	117
papers	citations	h-index	g-index
144	144	144	12876
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination. Journal of Virology, 1999, 73, 152-160.	1.5	2,383
2	Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection. Journal of Experimental Medicine, 2001, 194, 1395-1406.	4.2	1,091
3	Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2992-2997.	3 . 3	991
4	Eukaryotic start and stop translation sites. Nucleic Acids Research, 1991, 19, 3185-3192.	6. 5	631
5	Protection against persistence of hepatitis C. Lancet, The, 2002, 359, 1478-1483.	6.3	426
6	Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 + T Cells. Journal of Virology, 2006, 80, 6441-6457.	1.5	377
7	Genetic Epidemiology of Hepatitis C Virus throughout Egypt. Journal of Infectious Diseases, 2000, 182, 698-707.	1.9	336
8	Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART. JAMA - Journal of the American Medical Association, 2005, 293, 817.	3.8	323
9	Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection. Gastroenterology, 2010, 138, 315-324.	0.6	316
10	Cellular immune selection with hepatitis C virus persistence in humans. Journal of Experimental Medicine, 2005, 201, 1741-1752.	4.2	278
11	Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy. American Journal of Medicine, 1996, 101, 68-76.	0.6	256
12	Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C. Gastroenterology, 2008, 135, 226-233.	0.6	251
13	Acute hepatitis C. Lancet, The, 2008, 372, 321-332.	6.3	244
14	Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology, 2014, 59, 2140-2151.	3 . 6	230
15	Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology, 2005, 42, 104-112.	3.6	211
16	Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus. Gastroenterology, 2009, 136, 2377-2386.	0.6	207
17	HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy. JAMA - Journal of the American Medical Association, 2001, 286, 196.	3.8	196
18	Prospective Evaluation of Communityâ€Acquired Acuteâ€Phase Hepatitis C Virus Infection. Clinical Infectious Diseases, 2005, 40, 951-958.	2.9	195

#	Article	IF	CITATIONS
19	Genotypic Analysis of HIVâ€1 Drug Resistance at the Limit of Detection: Virus Production without Evolution in Treated Adults with Undetectable HIV Loads. Journal of Infectious Diseases, 2004, 189, 1452-1465.	1.9	186
20	Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. Journal of Experimental Medicine, 2005, 201, 1753-1759.	4.2	178
21	Cross-Genotype Immunity to Hepatitis C Virus. Journal of Virology, 2004, 78, 1575-1581.	1.5	175
22	Acute Hepatitis C Virus Structural Gene Sequences as Predictors of Persistent Viremia: Hypervariable Region 1 as a Decoy. Journal of Virology, 1999, 73, 2938-2946.	1.5	175
23	Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2575-E2584.	3.3	173
24	Humoral Immune Response in Acute Hepatitis C Virus Infection. Clinical Infectious Diseases, 2005, 41, 667-675.	2.9	172
25	Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy. Journal of Virology, 2006, 80, 4758-4770.	1.5	156
26	Gâ†'A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo. Journal of Virology, 2005, 79, 1975-1980.	1.5	154
27	A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children. Journal of Clinical Investigation, 2000, 105, 995-1003.	3.9	151
28	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight, 2017, 2, .	2.3	129
29	Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy. Journal of Virology, 2000, 74, 9028-9038.	1.5	121
30	Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure. Journal of Virology, 2002, 76, 9481-9492.	1.5	119
31	Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus. Journal of Virology, 2010, 84, 7018-7028.	1.5	116
32	Determinants of the Quantity of Hepatitis C Virus RNA. Journal of Infectious Diseases, 2000, 181, 844-851.	1.9	114
33	High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. Journal of Immunology, 2008, 181, 8215-8225.	0.4	114
34	The Role of Viral Introductions in Sustaining Community-Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and Egocentric Transmission Models. PLoS Medicine, 2014, 11, e1001610.	3.9	114
35	Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial. Journal of Infectious Diseases, 2011, 204, 1918-1926.	1.9	99
36	Needlestick Transmission of Hepatitis C. JAMA - Journal of the American Medical Association, 2002, 287, 2406.	3.8	98

#	Article	IF	CITATIONS
37	Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads. Journal of Virology, 2004, 78, 968-979.	1.5	98
38	Transmission of Human Immunodeficiency Virus Type 1 from a Patient Who Developed AIDS to an Elite Suppressor. Journal of Virology, 2008, 82, 7395-7410.	1.5	90
39	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host and Microbe, 2018, 24, 717-730.e5.	5.1	78
40	Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. Journal of Clinical Investigation, 2015, 125, 437-447.	3.9	78
41	Durable SARS-CoV-2 B cell immunity after mild or severe disease. Journal of Clinical Investigation, 2021, 131, .	3.9	76
42	Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. Journal of Clinical Investigation, 2020, 130, 6631-6638.	3.9	75
43	Use of Laser Capture Microdissection to Map Hepatitis C Virus–Positive Hepatocytes in Human Liver. Gastroenterology, 2013, 145, 1404-1413.e10.	0.6	74
44	Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection. Journal of Virology, 2010, 84, 5067-5077.	1.5	70
45	Comprehensive Genetic and Epigenetic Analysis of Occult Hepatitis B from Liver Tissue Samples. Clinical Infectious Diseases, 2008, 46, 1227-1236.	2.9	69
46	Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. Journal of Virology, 2015, 89, 8219-8232.	1.5	68
47	Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. Journal of Virology, 1995, 69, 7548-7558.	1.5	68
48	Hypervariable Region 1 Sequence Stability during Hepatitis C Virus Replication in Chimpanzees. Journal of Virology, 2000, 74, 3058-3066.	1.5	65
49	CMPK2 and BCL-G are associated with type 1 interferon–induced HIV restriction in humans. Science Advances, 2018, 4, eaat0843.	4.7	64
50	Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology, 2012, 55, 1684-1691.	3.6	63
51	Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire. Journal of Immunology, 2008, 181, 6435-6446.	0.4	61
52	Slow Human Immunodeficiency Virus Type 1 Evolution in Viral Reservoirs in Infants Treated with Effective Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2007, 23, 381-390.	0.5	59
53	Hepatitis C Virus Infection of Neuroepithelioma Cell Lines. Gastroenterology, 2010, 139, 1365-1374.e2.	0.6	59
54	Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor–Resistant HIVâ€1 among Recently Infected Infants Born in the United States. Journal of Infectious Diseases, 2007, 195, 1402-1410.	1.9	58

#	Article	IF	CITATIONS
55	PCR Detection of Adenovirus in a Bone Marrow Transplant Recipient: Hemorrhagic Cystitis as a Presenting Manifestation of Disseminated Disease. Journal of Clinical Microbiology, 1999, 37, 686-689.	1.8	57
56	Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. Aids, 2009, 23, 2397-2404.	1.0	55
57	Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E82-E91.	3.3	52
58	Prevalence of Congenital Homocystinuria in Denmark. New England Journal of Medicine, 1999, 340, 1513-1513.	13.9	50
59	Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathogens, 2017, 13, e1006235.	2.1	47
60	Presence in India of HIV Type 1 Similar to North American Strains. AIDS Research and Human Retroviruses, 1994, 10, 1039-1041.	0.5	45
61	Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes. PLoS Computational Biology, 2014, 10, e1003934.	1.5	45
62	Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies. Journal of Virology, 2001, 75, 3259-3267.	1.5	42
63	Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy. Journal of Virology, 2009, 83, 9731-9742.	1.5	41
64	Evolution of the HIV-1 nefgene in HLA-B*57 Positive Elite Suppressors. Retrovirology, 2010, 7, 94.	0.9	39
65	A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. Journal of Virological Methods, 2006, 136, 238-247.	1.0	37
66	Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. Journal of Virology, 2015, 89, 8206-8218.	1.5	37
67	Assessment of Hepatitis C Virus Sequence Complexity by Electrophoretic Mobilities of Both Single-and Double-Stranded DNAs. Journal of Clinical Microbiology, 1998, 36, 2982-2989.	1.8	36
68	Dynamics of SEN Virus Infection among Injection Drug Users. Journal of Infectious Diseases, 2001, 184, 1315-1319.	1.9	35
69	Identification of Nevirapineâ€Resistant HIVâ€1 in the Latent Reservoir after Singleâ€Dose Nevirapine to Prevent Motherâ€toâ€Child Transmission of HIVâ€1. Journal of Infectious Diseases, 2009, 199, 1301-1309.	1.9	35
70	High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology, 2009, 50, 1765-1772.	3.6	35
71	Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. Journal of Clinical Investigation, 2019, 129, 4786-4796.	3.9	33
72	A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients. Journal of Virology, 2005, 79, 5185-5202.	1.5	32

#	Article	IF	Citations
73	Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore–Washington metropolitan area. JCl Insight, 2021, 6, .	2.3	31
74	Progression of Fibrosis during Chronic Hepatitis C Is Associated with Rapid Virus Evolution. Journal of Virology, 2007, 81, 6513-6522.	1.5	30
75	Sex and the genetic diversity of HIV-1. Nature Medicine, 2000, 6, 23-25.	15.2	29
76	CD4+T Cell Depletion in an Untreated HIV Type 1–Infected Human Leukocyte Antigen–B*5801–Positive Patient with an Undetectable Viral Load. Clinical Infectious Diseases, 2008, 46, e78-e82.	2.9	29
77	Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology, 2012, 422, 174-184.	1.1	29
78	Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection. Journal of Immunology, 2012, 188, 5177-5188.	0.4	28
79	No evidence of SARS-CoV-2 reverse transcription and integration as the origin of chimeric transcripts in patient tissues. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
80	Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles. Journal of General Virology, 2016, 97, 2883-2893.	1.3	27
81	Molecular epidemiology of HIV-1 subtypes in southern China. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 356-62.	0.9	26
82	Accurate Representation of the Hepatitis C Virus Quasispecies in 5.2-Kilobase Amplicons. Journal of Clinical Microbiology, 2004, 42, 4223-4229.	1.8	25
83	Maternal Neutralizing Antibody and Transmission of Hepatitis C Virus to Infants. Journal of Infectious Diseases, 2008, 198, 1651-1655.	1.9	25
84	Analysis of HIV Diversity Using a High-Resolution Melting Assay. AIDS Research and Human Retroviruses, 2010, 26, 913-918.	0.5	24
85	A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology, 2016, 90, 3773-3782.	1.5	24
86	An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern. Clinical Infectious Diseases, 2022, 74, 1419-1428.	2.9	24
87	Constraints on Viral Evolution during Chronic Hepatitis C Virus Infection Arising from a Common-Source Exposure. Journal of Virology, 2012, 86, 12582-12590.	1.5	23
88	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight, 2022, 7, .	2.3	23
89	Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral Therapy. AIDS Patient Care and STDs, 2008, 22, 545-552.	1.1	22
90	Computational Reconstruction of Bole1a, a Representative Synthetic Hepatitis C Virus Subtype 1a Genome. Journal of Virology, 2012, 86, 5915-5921.	1.5	21

#	Article	IF	Citations
91	Human Immunodeficiency Virus Type 1 env and p17gag Sequence Variation in Polymerase Chain Reaction-Positive, Seronegative Injection Drug Users. Journal of Infectious Diseases, 1995, 171, 797-804.	1.9	19
92	Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. Journal of Virology, 2015, 89, 9454-9464.	1.5	19
93	Rapid and sensitive detection of viral nucleic acids using silicon microchips. Analyst, The, 2018, 143, 2596-2603.	1.7	19
94	Predominance of defective proviral sequences in an HIV + long-term non-progressor. Immunology Letters, 1996, 51, 3-6.	1.1	18
95	Autologous Strain-Specific Cytolytic T Lymphocyte Responses Directed against Human Immunodeficiency Virus Type 1 Env. AIDS Research and Human Retroviruses, 1998, 14, 3-13.	0.5	18
96	CD4 ⁺ T-Cellâ€"Dependent Reduction in Hepatitis C Virusâ€"Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2015, 212, 914-923.	1.9	18
97	Interferonâ€free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <scp>SOUND</scp> â€C3, a Phase 2b study. Liver International, 2015, 35, 417-421.	1.9	18
98	Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group. Clinical Pharmacology and Therapeutics, 2014, 96, 162-165.	2.3	17
99	Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India. Indian Journal of Medical Research, 2010, 132, 706-14.	0.4	17
100	The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS) BMC Gastroenterology, 2011, 11, 107.	0.8	15
101	Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users. Hepatology, 2012, 56, 544-554.	3.6	15
102	Molecular Epidemiology of HIV Type 1 in Singapore and Identification of Novel CRF01_AE/B Recombinant Forms. AIDS Research and Human Retroviruses, 2011, 27, 1135-1137.	0.5	14
103	Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology, 2014, 60, 477-486.	3.6	14
104	Characterization of novel recombinant HIV-1 genomes using the branching index. Virology, 2003, 316, 116-125.	1,1	13
105	Genetic Divergence of Hepatitis C Virus: The Role of HIV-Related Immunosuppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 136-141.	0.9	12
106	Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infection, Genetics and Evolution, 2018, 58, 77-82.	1.0	12
107	Monomer sequence determination of carbohydrates using fast-atom bombardment mass spectrometry of periodate-oxidized acetate ester derivatives. Carbohydrate Research, 1990, 197, 1-14.	1.1	11
108	Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore. Infection, Genetics and Evolution, 2020, 77, 104078.	1.0	11

#	Article	IF	CITATIONS
109	Recrudescence of Treated Neurosyphilis in a Patient With Human Immunodeficiency Virus. Mayo Clinic Proceedings, 1999, 74, 53-56.	1.4	10
110	HIVâ€1 Evolution Following Transmission to an HLAâ€8*5801â€Positive Patient. Journal of Infectious Diseases, 2009, 200, 1820-1824.	1.9	9
111	Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals. Aids, 2017, 31, 1405-1414.	1.0	9
112	Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore. BMC Infectious Diseases, 2020, 20, 815.	1.3	9
113	Plasma virome and the risk of blood-borne infection in persons with substance use disorder. Nature Communications, 2021, 12, 6909.	5.8	8
114	Ecchymoses and eschars at sites of injection. Lancet, The, 1997, 349, 1364.	6.3	7
115	Generative optical modeling of whole blood for detecting platelets in lens-free images. Biomedical Optics Express, 2020, 11, 1808.	1.5	7
116	Drivers and barriers to workplace-based HIV self-testing among high-risk men in Uganda: a qualitative study. BMC Public Health, 2021, 21, 1002.	1.2	6
117	Spatiotemporal Phylodynamics of Hepatitis C Among People Who Inject Drugs in India. Hepatology, 2021, 74, 1782-1794.	3.6	6
118	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. PLoS Pathogens, 2022, 18, e1010179.	2.1	6
119	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. Journal of Clinical Investigation, 2022, 132, .	3.9	5
120	Interleukinâ€18 and tumor necrosis factorâ€Î± are elevated in solid organ transplant recipients with possible cytomegalovirus endâ€organ disease. Transplant Infectious Disease, 2021, 23, e13682.	0.7	4
121	Severe pruritus after completing pegylated interferon for hepatitis C. Aids Reader, 2008, 18, 562-5.	0.3	3
122	Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. Infection, Genetics and Evolution, 2019, 71, 1-6.	1.0	2
123	Building Leadership Capacity for Mission Execution in a Large Academic Department of Medicine. American Journal of Medicine, 2019, 132, 535-543.	0.6	2
124	Decreased Activated CD4 ⁺ T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4 ⁺ T Cell Recovery. Viral Immunology, 2021, 34, 622-631.	0.6	2
125	A 61-Year-Old Female with a Prior History of Tuberculosis Presenting with Hemoptysis. Clinical Infectious Diseases, 2011, 52, 910-910.	2.9	1
126	Molecular epidemiology of GB type C virus among individuals exposed to hepatitis C virus in Cameroon. Mental Illness, 2013, 4, 1.	0.8	1

#	Article	IF	CITATIONS
127	Impact of Point-of-Care Diagnostics on Clinical Decision-making in Low- and Middle-Income Countries. journal of applied laboratory medicine, The, 2018, 3, 456-459.	0.6	1
128	An Optical Model of Whole Blood for Detecting Platelets in Lens-Free Images. Lecture Notes in Computer Science, 2019, , 140-150.	1.0	1
129	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) exposure investigations using genomic sequencing among healthcare workers and patients in a large academic center. Infection Control and Hospital Epidemiology, 2022, , 1-4.	1.0	1
130	Volatilization of mercury from natural water by a broad-spectrum Hg-resistantBacillus pasteurii strain DR2. The Environmentalist, 1996, 16, 179-185.	0.7	0
131	Characterization of novel recombinant HIV-1 genomes using the branching index. Virology, 2003, 316, 116-116.	1.1	0
132	Genetic Linkage of Hepatitis B Virus in Peripheral Blood Leukocytes Provides Evidence for Contamination. Journal of Virology, 2010, 84, 2184-2186.	1.5	0
133	It's 10 pm ; Do You Know Where Your Data Are?. Circulation Research, 2017, 120, 1551-1554.	2.0	0
134	Joint Holographic Detection and Reconstruction. Lecture Notes in Computer Science, 2019, , 664-672.	1.0	0
135	The Brief Case: The Fly Who Cried Wohlf. Journal of Clinical Microbiology, 2022, 60, .	1.8	0
136	Closing the Brief Case: The Fly Who Cried Wohlf. Journal of Clinical Microbiology, 2022, 60, .	1.8	0